Brasília – Brazil is currently the fifth largest country in the world in number of registered biosimilars, consolidating its position as the leader in Latin America. Biologicals and biosimilars already account for 30% of the pharmaceutical sector’s total revenue, moving R$ 48.5 billion in 2024, a 25.9% increase compared with 2023.

According to PróGenéricos, its member companies increased their market share in units sold from 1.45% in 2020 to 7.33% in 2024, representing a growth of 1,589%. Brazil now has 63 biosimilars registered, distributed among 15 manufacturers, with 80 presentations available.

Major producers active in the country include Aché, Brainfarma, Eurofarma, EMS, Fresenius Kabi and Sandoz, responsible for molecules such as adalimumab, enoxaparin, insulin glargine, filgrastim and trastuzumab.

Source: Panorama Farmacêutico

Would you like a complete analysis on this? Contact us at pharmabrnews@gmail.com